To test the sensitivity of NUP98-r AML to the Menin inhibitor, we used transgenic cells ectopically expressing NUP98 fusions and patient-derived primary AML cells containing NUP98 rearrangements. The gene discussed is NUP98; the disease is acute myeloid leukemia.